For following the competition: what moved in each program, several studies read as one move.
- 131I-apamistamab
- Anti-CD33-CLL1 CAR-T cells (ICG415) following lymphodepleting fludarabine and cyclophosphamide
Mondays · ranked, phase 3 first · readouts ahead · See a sample brief
Add Leukemia, Myeloid to watchlistEvery Monday by email · turn it off any timePro · free during the beta